Effect of Daily Tadalafil 5 mg on Lower Urinary Tract Symptoms and Erectile Function in Men Over 50 Years: A Prospective Single-Arm Observational Study

Benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) frequently coexist in aging men and significantly impair quality of life. Tadalafil has emerged as a potential treatment targeting both conditions. To evaluate the efficacy of daily tadalafil 5 mg in improving lower urinary tract symptoms (LUTS) and erectile function in men aged ≥50 years. This prospective observational study included 130 men presenting with LUTS and ED. The study was conducted from January 2018 to December 2023. All patients received tadalafil 5 mg once daily for 12 weeks. Outcomes were assessed using the International Prostate Symptom Score (IPSS) and International Index of Erectile Function-5 (IIEF-5). Statistical significance was set at p < 0.05. The mean IPSS score significantly decreased from 18 to 9 (p < 0.05), while the mean IIEF-5 score increased from 12 to 18 (p < 0.05). Improvement in both LUTS and ED was observed in 69.2% of patients. Daily tadalafil 5 mg was associated with significant improvements in both lower urinary tract symptoms and erectile function over a 12-week treatment period.